Product details

This is part of a case series. The Novartis Venture Fund (NVF) is considering investing in a start-up, Genedata, and must take into account the valuation analysis by both the start-up as well as Venture Valuation - an independent boutique organisation that specialises in valuing high growth potential start-ups. NVF uses the Venture Valuation inputs to determine how best to structure the next round of financing for Genedata and the case requires the reader to discuss and analyse pricing, further financing requirements, and exit strategy for the fund.